Orthocell Receives U.S. Approval to Distribute Remplir™ Nerve Repair Device in Military and VA Hospitals

Thu, 16 Apr 2026 18:59:00 +0200

Orthocell Limited, an Australian regenerative medicine company, has obtained approval for its Remplir™ nerve repair device to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks. This approval grants access to approximately 51 DoD military hospitals and 170 VA medical centers, representing a substantial expansion of the company’s presence in the U.S. market. Orthocell plans to leverage its existing U.S. distributor network, which covers 17 states, to target military and VA surgeons directly. The device has already been successfully used in 23 surgical procedures on injured soldiers in Ukraine, demonstrating its portability, ease of use, and suitability for treating major traumatic injuries commonly encountered in military healthcare settings. Previously, Orthocell had secured 32 Value Analysis Committee approvals providing access to over 115 hospitals, with an additional 57 applications pending. The company sees this approval as a ma